IP Library › Granted Patent US 12,594,296
Granted Patent B2
US 12,594,296 · App. 18/430,984 · Granted Apr 7, 2026

Methods for treatment or prevention of damage resulting from radiation, trauma or shock

Inventors: Shenda M. Baker (Upland, CA); William P. Wiesmann (Chevy Chase, MD)
Assignee: SYNEDGEN, INC.
A61K31/726Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,594,296
App. No.
18/430,984
Granted
Apr 7, 2026
Kind
B2
Abstract

Described herein are methods of treating a subject that has been or will be exposed to radiation, trauma or shock, the method comprising identifying a subject that has been or will be exposed to radiation, and treating the subject with a compound that treats, reduces the severity or delays the onset of sepsis or reduces the likelihood of mortality in a subject upon administration of a therapeutically effective amount the compound to the subject.

Claims (18)

1 . A method of reducing the severity or delaying the onset of sepsis or reducing the likelihood of mortality in a subject, the method comprising identifying a subject that will be exposed to radiation from a dirty bomb, accidental nuclear incident, or therapeutic treatment; and prior to exposure to radiation, administering a therapeutically effective amount of a compound to the subject,

wherein the compound is a compound of Formula (I):

wherein:

n is an integer between 20 and 6000; and

each R 1 is independently selected for each occurrence from hydrogen, acetyl,

wherein at least 25% of R 1 substituents are H, at least 1% of R 1 substituents are acetyl,

and at least 2% of R 1 substituents are

thereby reducing the severity or delaying the onset of sepsis or reducing the likelihood of mortality in the subject.

2 . The method of claim 1 , wherein the subject is at risk of developing sepsis as a result of exposure to radiation.

3 . The method of claim 1 , wherein the subject has or is at risk of having reduced nutrient absorption, pain, nausea, diarrhea, and/or weight loss resulting from radiation.

4 . The method of claim 1 , wherein the subject has necrotizing enterocolitis, necrotic enteritis, short bowel syndrome, or short gut syndrome.

5 . The method of claim 1 , wherein the compound is functionalized at between 18% and 30%.

6 . The method of claim 1 , wherein the molecular weight of the compound is from 50 to 150 kDa.

7 . The method of claim 1 , wherein the polydispersity index of the compound is from 1.0 to 2.5.

8 . The method of claim 1 , wherein the radiation is in an amount sufficient to produce 30% to 80% lethality.

9 . The method of claim 1 , wherein the radiation is from a dirty bomb or accidental nuclear incident.

10 . The method of claim 1 , wherein the radiation is from therapeutic treatment.

11 . The method of claim 10 , wherein the therapeutic treatment is bone marrow transplant therapy.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2024
From: BAKER, SHENDA; WIESMANN, WILLIAM P.
To: SYNEDGEN, INC.
Reel/Frame 066394/0030 →
Continuity (7)
Continuation 17150406 · Jan 15, 2021
Continuation 16896562 · Jun 9, 2020
Continuation 16007503 · Jun 13, 2018
Continuation 14033332 · Sep 20, 2013
Provisional Application 61737576 · Dec 14, 2012
Provisional Application 61703703 · Sep 20, 2012
Related Publication 20250000893A1 · Jan 2, 2025
References Cited (99)
US 4409205A · Shively · 1983 [cited by applicant]
US 4532134A · Malette et al. · 1985 [cited by applicant]
US 5610184A · Shahinian, Jr. · 1997 [cited by applicant]
US 6114382A · Moretti · 2000 [cited by applicant]
US 6323189B1 · Hardinge-Lyme · 2001 [cited by applicant]
US 6962151B1 · Knoch et al. · 2005 [cited by applicant]
US 7618382B2 · Vogel et al. · 2009 [cited by applicant]
US 8119780B2 · Baker et al. · 2012 [cited by applicant]
US 8399635B2 · Baker et al. · 2013 [cited by applicant]
US 8658775B2 · Baker et al. · 2014 [cited by applicant]
US 8916542B2 · Baker et al. · 2014 [cited by applicant]
US 9012429B2 · Baker et al. · 2015 [cited by applicant]
US 9029351B2 · Baker et al. · 2015 [cited by applicant]
US 9234050B2 · Baker et al. · 2016 [cited by applicant]
US 9439925B2 · Baker et al. · 2016 [cited by applicant]
US 9732164B2 · Baker et al. · 2017 [cited by applicant]
US 10022393B2 · Baker et al. · 2018 [cited by applicant]
US 10716803B2 · Baker et al. · 2020 [cited by applicant]
US 20060029675A1 · Ginther · 2006 [cited by applicant]
US 20060149171A1 · Vogel et al. · 2006 [cited by applicant]
US 20070281904A1 · Baker et al. · 2007 [cited by applicant]
US 20090202430A1 · Hoemann et al. · 2009 [cited by applicant]
US 20090274770A1 · Gammelsaeter et al. · 2009 [cited by applicant]
US 20100130443A1 · Baker et al. · 2010 [cited by applicant]
US 20110206654A1 · Hodin et al. · 2011 [cited by applicant]
US 20110263504A1 · Cerami et al. · 2011 [cited by applicant]
US 20120295355A1 · Baker et al. · 2012 [cited by applicant]
US 20120301408A1 · Baker et al. · 2012 [cited by applicant]
US 20120329751A1 · Baker et al. · 2012 [cited by applicant]
US 20130164311A1 · DeCarlo et al. · 2013 [cited by applicant]
US 20130210761A1 · Baker et al. · 2013 [cited by applicant]
US 20140080785A1 · Baker et al. · 2014 [cited by applicant]
US 20140221308A1 · Baker et al. · 2014 [cited by applicant]
US 20150031610A1 · Baker et al. · 2015 [cited by applicant]
US 20150224044A1 · Baker et al. · 2015 [cited by applicant]
US 20160022564A1 · Townsend et al. · 2016 [cited by applicant]
US 20160022730A1 · Baker et al. · 2016 [cited by applicant]
US 20170119810A1 · Baker et al. · 2017 [cited by applicant]
US 20170136056A1 · Baker et al. · 2017 [cited by applicant]
CA 2763092A1 · 2010 [cited by applicant]
CN 1965650A · 2007 [cited by applicant]
JP 2003012702A · 2003 [cited by applicant]
JP 2008507380A · 2008 [cited by applicant]
KR 20180025649A · 2018 [cited by applicant]
WO WO9945945A1 · 1999 [cited by applicant]
WO WO0030609A1 · 2000 [cited by applicant]
WO WO2004026200A2 · 2004 [cited by applicant]
WO WO2004068971A1 · 2004 [cited by applicant]
WO WO2004071186A1 · 2004 [cited by applicant]
WO WO2006014917A2 · 2006 [cited by applicant]
WO WO2007142704A3 · 2008 [cited by applicant]
WO WO2010021930A1 · 2010 [cited by applicant]
WO WO2011028967A1 · 2011 [cited by applicant]
WO WO2011127144A1 · 2011 [cited by examiner]
WO WO2014047506A1 · 2014 [cited by applicant]
WO WO2016040899A1 · 2016 [cited by applicant]
WO WO2018202783A1 · 2018 [cited by applicant]
Alsarra et al. “Chitosan topical gel formulation in the management of burn wounds” International Journal of Biological Macromolecules (2009) vol. 45. pp 16-21. [cited by applicant]
Bayat A. et al., “Skin scarring.” BMJ, 2003; 326:88-92. [cited by applicant]
Brook et al. “Management of Postirradiation Infection: Lessons Learned from Animal Models” Military Medicine, vol. 169, 2004, pp. 194-197. [cited by applicant]
Carden et al, Journal of Pathology, 2000, 190, 255-66. [cited by applicant]
CDC Fact Sheet on ARS. 2005. [cited by applicant]
Doi K. et al., J Clin Invest. 2009; 119(10):2868-78. [cited by applicant]
Fang RC and Mustoe FA, “Animal models of wound healing: utility in transgenic mice.” J Biomater Sci Polym Ed. 2008; 19(8):989-1005. [cited by applicant]
Gorbach, Medical Microbiology, 4th Ed., 1996, pp. 1-9. [cited by applicant]
Grose R. and Werner S., “Wound healing studies in transgenic and knockout mice. A review.” Methods Mol Med. 2003; 78:191-216. [cited by applicant]
Hafer et al. “The NIAID Radiation Countermeasures Program Business Model” Biosecurity and Bioterrorism, vol. 8, No. 4, 2010, pp. 357-363. [cited by applicant]
Headley et al, Am. Fam. Physician 2003, 68, 323-28. [cited by applicant]
International Search Report and Written Opinion for PCT/US13/061027 dated Feb. 4, 2014. [cited by applicant]
Ito et al. “Anti-ulcer Effects of Chitin and Chitosan, Healthy Foods, in Rats”, Jp. J. Pharmacol. 82, pp. 218-225 (2000). [cited by applicant]
Jawad et al. “Effect of Chitosan Sheets on Wound Healing” Basrah Journal of Veterinary Research (2007) vol. 6, pp. 81-95. [cited by applicant]
Kara Co, “Animal models of sinusitis: relevance to human disease.” Curr Allergy Asthma Rep. 2004; 4(6):496-9. [cited by applicant]
Kweon et al. “Preparation of water-soluble chitosan/heparin complex and its application as wound healing accelerator” Biomaterials (2003) vol. 24, pp. 1595-1601. [cited by applicant]
Mathers et al. , Invest Opthalmol Vis Sci. 1989; 30(11 ):2403-6. [cited by applicant]
Matsubara M., Invest Ophthalmol Vis Sci. 1991; 32(13):3221-37. [cited by applicant]
Nakajima M. et al. , otolaryngology—Head and Neck Surgery, 131(2), 198-199, (2004). [cited by applicant]
Nemzek JA and Kim J, Comp Med. 2009; 59(4):321-30. [cited by applicant]
Olerud JE, “Models for diabetic wound healing and healing into percutaneous devices.” J Biometer Sci Polym Ed. 2008; 19(8): 1007-20. [cited by applicant]
Roques C. et al., Lower Extremity Wounds, 2007; 6(4):249-53. [cited by applicant]
Santos Heredero FX et al., Annals of Burns and Fire Disasters, IX—n. 2 (Jun. 1996). [cited by applicant]
Schon MP, “Animal models of psoriasis: a critical appraisal.” Exp Dermatol. 2008; 17(8):703-12. [cited by applicant]
Singh et al. “Medical Countermeasures for Radiation Exposure and Related Injuries: Characterization of Medicines, FDA-Approval Status and Inclusion into the Strategic National Stockpile” Health Physics, vol. 108, No. 6,… [cited by applicant]
Sonis ST et al., “An Animal Model for Mucositis Induced by Cancer Chemotherapy”, Oral Surg Oral Med Oral Pathol, 69(4), pp. 437-443, (1990). [cited by applicant]
Stevenson JM et al., Methods Mal Med. 2003; 78:95-105. [cited by applicant]
Supplementary European Search Report from corresponding European Application EP 11766639 dated Jul. 23, 2013. [cited by applicant]
Surgwiki, 2012, 10th January, pp. 1-7. [cited by applicant]
The Merck Manual, 1992, pp. 1276-1277 and p. 1285. [cited by applicant]
Thuijls, et al., “Intestinal barrier loss in sepsis”, Netherlands Journal of Critical Care, 15 {4): 199-203, 2011. [cited by applicant]
Ueno et al. “Topical formulations and wound healing applications of chitosan” Advanced Drug Delivery Reviews (2001) vol. 52, pp. 105-115. [cited by applicant]
Mitsuyama K, et al. “Interleukin-10 in the Pathophysiology of Inflammatory Bowel Disease: Increased Serum Concentrations During the Recovery Phase,” Mediators of inflammation (2006) Article ID 26875, pp. 1-7. [cited by applicant]
Lin W, et al. “Effects of crab shell's chitosan administration on cytokine secretion by lipopolysaccharide-stimulated splenocytes from BALB/c mice,” Taiwan Nongye Huaxue Yu Shipin Kexue (2009), vol. 47, No. 3, pp. 119-1… [cited by applicant]
Burns et al. (Docum. Ophthal. Proc. Series, vol. 18, 245-251; Hockwin et al. (eds.), Progress in Anterior Eye Segment Research and Practice © Dr W. Junk b.v. Publishers 1979). [cited by applicant]
Junping Li, et al. “Drug-Induced Ocular Disorders”, Drug Safety 2008; 31 (2); p. 127-141. [cited by applicant]
Wolfgang Bernauer, Ocular surface problems following topial medication, Klin Monatsbl Augenheilkd 2002; 219: 240-242. [cited by applicant]
International Search Report and Written Opinion for corresponding International Application No. PCT/US2017/22698 dated Jun. 9, 2017. [cited by applicant]
Extended European Search Report for EP17767522 mailed on Aug. 26, 2019 (4 pages). [cited by applicant]
Tang, H et al, “Antibacterial action of a novel functionalized chitosan-arginine against Gram-negative bacteria” [cited by applicant]
Pfister et al., “Topical ascorbate decreases the incidence of corneal ulceration after experimental al-kali burns”, Investigative Ophthalmology & Visual Science (1978), 17( 10), 1019-24. [cited by applicant]
Pharmaceutical Solutions for Oral Administration (Chapter 1, pp. 1-24; 2008). [cited by applicant]